RIGL Stock Forecast: Rigel Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$40
−2.67% on the day

The 4 Wall Street analysts covering Rigel Pharmaceuticals, Inc. hold a median 12-month price target of $55 — +37.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 84 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$754.9M
Ticker Nerd rank
84/ 100
Median analyst target
$55
Analysts covering
4
Revenue$78.7M−22.6% y/y
Operating income$23.6M
Net income$17.3M
Free cash flow−$39.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.8%
1M
−16.7%
YTD
−6.4%
1Y
−8.6%
From 52W high
−22.1%
From 52W low
+57.6%
$25
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Rigel Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
84/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
97
Momentum
89
Issuance
80
Growth
57
Revisions
54
Volatility
47
Accruals
10

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RIGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RIGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80$90Jan 26Apr 26Jul 26Oct 26RIGLHigh $86Median $55Low $47

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
2
Buy
2
Hold
0
Sell
$47
Low
$55
Median
$86
High

The green dot is the last close — the median target sits +37.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Nov 2026CitigroupMaintainsBuy$83 → $86
6 Nov 2026Cantor FitzgeraldMaintainsNeutral$43 → $47
19 Oct 2026HC Wainwright & Co.ReiteratesBuy$85
17 Aug 2026Piper SandlerMaintainsNeutral$40 → $49
14 Aug 2026HC Wainwright & Co.MaintainsBuy$57 → $85
18 June 2026Cantor FitzgeraldMaintainsNeutral—
2 June 2026HC Wainwright & Co.ReiteratesBuy$57
27 May 2026HC Wainwright & Co.ReiteratesBuy$57
22 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026CitigroupMaintainsBuy—
7 May 2026CitigroupMaintainsBuy—
5 Nov 2025Cantor FitzgeraldMaintainsNeutral—
5 Nov 2025JefferiesUpgradeBuy—
8 Oct 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025Cantor FitzgeraldMaintainsNeutral—
7 May 2025Cantor FitzgeraldMaintainsNeutral—
6 Mar 2025CitigroupMaintainsBuy—
5 Mar 2025B. Riley SecuritiesMaintainsNeutral—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RIGL.

Market Radar

This page is one stock. Monday covers all of them.

RIGL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RIGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Rigel Pharmaceuticals, Inc. returned −8.6% against +6.9% for the S&P 500, dividends included.

RIGL vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26RIGLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RIGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−2.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 90% of US stocks

Price / sales
2.6×

Cheaper than 41% of US stocks

Price / book
1.7×

Cheaper than 50% of US stocks

EV / EBITDA
8.3×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−52.7%

Higher than 10% of US stocks

Gross margin
89.2%

Higher than 96% of US stocks

Operating margin
26.3%

Higher than 85% of US stocks

Net margin
—
Returns & dividend
Return on equity
109.2%

Higher than 97% of US stocks

Return on assets
12.4%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rigel Pharmaceuticals, Inc. has a market value of $754.9M and an enterprise value of $663.4M.

  • Revenue in the twelve months to 30 June 2026: $276.8M. The latest quarter shrank 22.6% year on year.

  • Net income over the same four quarters: $321.9M, a 116.3% net margin.

  • Diluted earnings per share, trailing twelve months: $16.32.

  • Free cash flow in the twelve months to 30 June 2026: $9.0M.

  • Shares outstanding: 18.7M.

  • Trailing P/E: 2.5×; forward P/E: 8.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Rigel Pharmaceuticals, Inc. employs 172 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

RIGL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RIGLRigel Pharmaceuticals, Inc.$754.9M84
OBXObsidian Therapeutics, Inc.$740.7M36
ARDXArdelyx, Inc.$751.6M57
GLUEMonte Rosa Therapeutics, Inc.$729.9M48
SNDXSyndax Pharmaceuticals, Inc.$757.9M58
ORICOric Pharmaceuticals, Inc.$761.9M53
VSTMVerastem, Inc.$769.1M39

Take a look at RIGL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Rigel Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RIGL

What is the RIGL stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Rigel Pharmaceuticals, Inc. have a median 12-month price target of $55, with estimates ranging from $47 to $86. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RIGL stock a buy right now?

Of the 4 analysts covering Rigel Pharmaceuticals, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rigel Pharmaceuticals, Inc. 84 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RIGL?

As at 21 Nov 2026, Rigel Pharmaceuticals, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will RIGL stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +37.2% from the last close, and Ticker Nerd's factor model ranks Rigel Pharmaceuticals, Inc. 84 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RIGL stock forecast for 2030?

No analyst covering Rigel Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RIGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $86 over the next 12 months.

How has RIGL stock performed over the past year?

Rigel Pharmaceuticals, Inc. returned -8.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rigel Pharmaceuticals, Inc. do?

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. The company’s current portfolio centers on commercial products and clinical-stage programs that address blood cancers and related immune-driven conditions, with an emphasis on targeted small-molecule medicines.

Company

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. The company’s current portfolio centers on commercial products and clinical-stage programs that address blood cancers and related immune-driven conditions, with an emphasis on targeted small-molecule medicines. Its marketed therapies support treatment in specialized physician markets, including hematology and oncology, while its research pipeline includes additional candidates designed to modulate key signaling pathways involved in disease progression. Rigel Pharmaceuticals also works through collaboration and licensing activities that support the development and commercialization of its products. Headquartered in South San Francisco, California, and founded in 1996, Rigel Pharmaceuticals plays a focused role in the biopharmaceutical market by supplying therapies for complex conditions with limited treatment options.

CEO Mr. Raul R. Rodriguez · 172 employees · United States · https://www.rigel.com